Literature DB >> 18534340

Middle fossa approach for acoustic tumor removal. 1992.

William F House1, Clough Shelton.   

Abstract

The middle fossa approach is useful for the removal of small acoustic tumors when hearing preservation is possible. This approach provides complete exposure of the contents of the internal auditory canal and positive facial nerve identification. Because access to the posterior fossa is limited, the middle fossa approach is most appropriate for tumors with less than 5 mm extension into the cerebellopontine angle. With the introduction of gadolinium-enhanced magnetic resonance imaging, very small acoustic tumors are diagonosed more frequently, and the middle fossa approach is well-suited for the removal of these tumors.

Entities:  

Mesh:

Year:  2008        PMID: 18534340     DOI: 10.1016/j.nec.2008.02.009

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  4 in total

1.  Euclidean Relationship between the Superior Semicircular Canal and the Arcuate Eminence.

Authors:  Aida Nourbakhsh; Yang Tang; Brian S DiPace; Daniel H Coelho
Journal:  J Neurol Surg B Skull Base       Date:  2019-03-12

2.  Revising the Indications of Transtemporal Surgical Approaches in the Modern Endoscopic Era of Skull Base Surgery: A Dying Art.

Authors:  Ravi Sankar Manogaran; Raj Kumar; Arulalan Mathialagan; Anant Mehrotra; Amit Keshri; Neha Singh; Govind S Bhuskute; Suyash Singh
Journal:  J Neurol Surg B Skull Base       Date:  2020-11-26

3.  Designing a 3D Printed Model of the Skull-Base: A Collaboration Between Clinicians and Industry.

Authors:  Youssuf Saleh; Rory Piper; Michael Richard; Sanjeeva Jeyaretna; Thomas Cosker
Journal:  J Med Educ Curric Dev       Date:  2022-03-07

4.  Surgical treatment of sporadic vestibular schwannoma in a series of 1006 patients.

Authors:  Z Zhang; Y Nguyen; D De Seta; F Y Russo; A Rey; M Kalamarides; O Sterkers; D Bernardeschi
Journal:  Acta Otorhinolaryngol Ital       Date:  2016-10       Impact factor: 2.124

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.